Lynparza shows PFS benefit in Phase III breast cancer study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Lynparza olaparib met the primary endpoint of improving progression-free survival (PFS) vs. chemotherapy in the Phase III OLYMPIAD trial to treat BRCA-mutated, HER2-negative breast cancer.

The 302-patient trial evaluated Lynparza vs. physician's choice of standard-of-care chemotherapy in patients with germline BRCA1 or BRCA2 mutations. AZ said the results are the first positive Phase III data for a PARP inhibitor in an indication other than ovarian cancer...